• Explore /
  • Poster
  • / Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

Abstract Poster

Authors

Luciano J. Costa

Luciano J. Costa

University of Alabama at Birmingham, Birmingham, AL

Luciano J. Costa , Sham Mailankody , Paul Shaughnessy , Parameswaran Hari , Jonathan L. Kaufman , Sarah Marie Larson , David Dingli , Kelvin Lee , Kristin Conte , Todd DeVries , Julia Piasecki , Meng Li , Ronald L. Dubowy , Myo Htut

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT03430011

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2537)

DOI

10.1200/JCO.2021.39.15_suppl.2537

Abstract #

2537

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ross Firestone

First Author: Weijia Fang

First Author: Salomon Manier

First Author: Lu Han